| pubmed-article:16056025 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C0038170 | lld:lifeskim |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C1154599 | lld:lifeskim |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C1335623 | lld:lifeskim |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C1415715 | lld:lifeskim |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:16056025 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:16056025 | pubmed:issue | 437 | lld:pubmed |
| pubmed-article:16056025 | pubmed:dateCreated | 2005-8-1 | lld:pubmed |
| pubmed-article:16056025 | pubmed:abstractText | Staphylococcus aureus and Staphylococcus epidermidis associated with implantable medical devices, are often difficult to treat with conventional antimicrobials. Formation of a biofilm and subsequent production of toxins are two distinct mechanisms considered important in foreign body infections. Staphylococcal virulence is caused by a complex regulatory process, which involves cell-to-cell communication through the release and response to chemical signals in a process known as quorum sensing. We explored the possibility of preventing infections by interfering with biofilm formation and toxin production using the quorum sensing inhibitor ribonucleic-acid-III-inhibiting peptide. In our studies ribonucleic-acid-III-inhibiting peptide prevented graft-associated infections caused by all species of staphylococci tested so far, including methicillin resistant S. aureus and S. epidermidis. Ribonucleic-acid-III-inhibiting peptide also enhances the effects of antibiotics and cationic peptides in the clearance of normally recalcitrant biofilm infections. Ribonucleic-acid-III-inhibiting peptide is nontoxic, highly stable, and no resistant strains have been found so far, suggesting that ribonucleic-acid-III-inhibiting peptide may be used to coat medical devices or used systemically to prevent infections. When the target of ribonucleic-acid-III activating protein activity is disrupted, biofilm formation is reduced under flow and static conditions and genes important for toxin production or biofilm formation are down-regulated. These in vitro data help explain why ribonucleic-acid-III-inhibiting peptide seems to be effective in preventing staphylococcal infections. | lld:pubmed |
| pubmed-article:16056025 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16056025 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:16056025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16056025 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16056025 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16056025 | pubmed:issn | 0009-921X | lld:pubmed |
| pubmed-article:16056025 | pubmed:author | pubmed-author:CostertonJ... | lld:pubmed |
| pubmed-article:16056025 | pubmed:author | pubmed-author:Dell'AcquaGio... | lld:pubmed |
| pubmed-article:16056025 | pubmed:author | pubmed-author:WilsonSuzanne... | lld:pubmed |
| pubmed-article:16056025 | pubmed:author | pubmed-author:StoodleyPaulP | lld:pubmed |
| pubmed-article:16056025 | pubmed:author | pubmed-author:BalabanNaomiN | lld:pubmed |
| pubmed-article:16056025 | pubmed:author | pubmed-author:FuxChristoph... | lld:pubmed |
| pubmed-article:16056025 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16056025 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16056025 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16056025 | pubmed:pagination | 48-54 | lld:pubmed |
| pubmed-article:16056025 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:meshHeading | pubmed-meshheading:16056025... | lld:pubmed |
| pubmed-article:16056025 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16056025 | pubmed:articleTitle | Prevention of staphylococcal biofilm-associated infections by the quorum sensing inhibitor RIP. | lld:pubmed |
| pubmed-article:16056025 | pubmed:affiliation | Tufts University School of Veterinary Medicine, Department of Biomedical Sciences, North Grafton, MA 01536, USA. naomi.balaban@tufts,edu | lld:pubmed |
| pubmed-article:16056025 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16056025 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16056025 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:16056025 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16056025 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16056025 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16056025 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16056025 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16056025 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16056025 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16056025 | lld:pubmed |
